Literature DB >> 15693854

Podoplanin as a marker for mesothelioma.

Noriko Kimura1, Itaru Kimura.   

Abstract

Podoplanin is a specific marker for lymph vessel endothelial cells. It was noted that podoplanin is expressed in reactive mesothelial cells. The utility of podoplanin for the histological diagnosis of tumors was then investigated, especially for mesothelioma. Immunohistochemical study of podoplanin was carried out in five malignant mesotheliomas and 118 other tumors including 93 adenocarcinomas, four squamous cell carcinomas, six gastrointestinal stromal tumors and five endocrine tumors. Immunoreactivity for podoplanin was demonstrated on the cell membrane of tumor cells for all mesotheliomas. All other tumors were negative for podoplanin. Among the many antibodies used for differential diagnosis of malignant mesothelioma, podoplanin has the potential to be an excellent tumor marker in both specificity and sensitivity. The utility of podoplanin as a marker for mesothelioma will be confirmed by further studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15693854     DOI: 10.1111/j.1440-1827.2005.01791.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  57 in total

1.  Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival.

Authors:  Haruhisa Kitano; Shun-Ichiro Kageyama; Stephen M Hewitt; Ryuji Hayashi; Yoshinori Doki; Yoshitomo Ozaki; Shozo Fujino; Mikiko Takikita; Hajime Kubo; Junya Fukuoka
Journal:  Arch Pathol Lab Med       Date:  2010-10       Impact factor: 5.534

2.  Clear cell mesothelioma presenting as an incarcerated abdominal hernia.

Authors:  Nelson G Ordóñez
Journal:  Virchows Arch       Date:  2005-07-14       Impact factor: 4.064

3.  Podoplanin expression in adamantinoma of long bones and osteofibrous dysplasia.

Authors:  Takeshi G Kashima; Arunthati Dongre; Adrienne M Flanagan; Pancras C W Hogendoorn; Richard Taylor; Nicholas A Athanasou
Journal:  Virchows Arch       Date:  2011-04-16       Impact factor: 4.064

4.  Podoplanin is expressed in subsets of tumors of the central nervous system.

Authors:  Junji Shibahara; Takeshi Kashima; Yoshinao Kikuchi; Akiko Kunita; Masashi Fukayama
Journal:  Virchows Arch       Date:  2006-01-13       Impact factor: 4.064

Review 5.  Podoplanin: a novel regulator of tumor invasion and metastasis.

Authors:  Qi Dang; Jie Liu; Juan Li; Yuping Sun
Journal:  Med Oncol       Date:  2014-08-21       Impact factor: 3.064

6.  Capture of mesothelioma cells with 'universal' CTC-chip.

Authors:  Kazue Yoneda; Yasuhiro Chikaishi; Taiji Kuwata; Takashi Ohnaga; Fumihiro Tanaka
Journal:  Oncol Lett       Date:  2017-12-14       Impact factor: 2.967

7.  Podoplanin is a negative regulator of Th17 inflammation.

Authors:  Alyssa N Nylander; Gerald D Ponath; Pierre-Paul Axisa; Mayyan Mubarak; Mary Tomayko; Vijay K Kuchroo; David Pitt; David A Hafler
Journal:  JCI Insight       Date:  2017-09-07

8.  Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas.

Authors:  Juan P Rodrigo; Dario García-Carracedo; María V González; Gonzalo Mancebo; Manuel F Fresno; Juana García-Pedrero
Journal:  Mol Cancer       Date:  2010-03-02       Impact factor: 27.401

9.  Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry.

Authors:  Helmut P Sandeck; Oluf D Røe; Kristina Kjærheim; Helena Willén; Erik Larsson
Journal:  Diagn Pathol       Date:  2010-07-06       Impact factor: 2.644

Review 10.  Podoplanin - a small glycoprotein with many faces.

Authors:  Maciej Ugorski; Piotr Dziegiel; Jaroslaw Suchanski
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.